Table 2—

Mean PFT values at baseline and the end of the trial

PFTAERx
SC
BaselineEnd of trialBaselineEnd of trial
n54505348
FVC95.6 ± 12.793.9 ± 14.297.2 ± 13.795.3 ± 14.4
Change from baseline analysis−2.3 ± 5.7−2.4 ± 5.8
AERx minus SC: 0.19 [−2.0 to 2.43], P = 0.86
n54505348
FEV197.6 ± 13.295.1 ± 14.496.2 ± 12.293.4 ± 13.9
Change from baseline analysis−3.2 ± 5.7−3.5 ± 5.8
AERx minus SC: 0.36 [−1.9 to 2.62], P = 0.75
n54505348
FEV1%104.6 ± 8.6103.9 ± 9.6101.1 ± 8.3100.1 ± 10.0
Change from baseline analysis−1.1 ± 5.4−2.1 ± 5.8
AERx minus SC: 1.07 [−1.1 to 3.28], P = 0.34
n51495348
TLC94.5 ± 13.493.4 ± 13.296.1 ± 12.996.1 ± 13.8
Change from baseline analysis−1.9 ± 6.0−0.86 ± 6.0
AERx minus SC: −1.08 [−3.5 to 1.30], P = 0.37
n53495248
DLCO91.3 ± 16.890.8 ± 18.493.6 ± 16.794.3 ± 16.5
Change from baseline analysis−2.0 ± 9.1−1.1 ± 8.9
AERx minus SC: −0.97 [−4.5 to 2.52], P = 0.58
  • Data are means ± SD unless otherwise indicated. The calculated mean difference of change from baseline after 12 weeks of treatment, the 95% CI, and P values are based on an ANOVA. The PFT values measured were as follows: forced vital capacity (FVC), forced expiratory volume in first second (FEV1), forced expiratory volume in first second/FVC (FEV%), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO). The unit for all these values was percent of predicted normal value.